Kite Pharma ($KITE) has teamed up with GE Global Research ($GE) to develop an automated production system for engineered T cell therapies. The development of such a system could help Kite control the cost of manufacturing its closely watched autologous immuno-oncology drugs. Dendreon, a pioneer in autologous cancer treatment, was dogged by high manufacturing costs throughout its attempt to make its cancer vaccine Provenge a success. Release